Autolus Therapeutics PLCNASDAQ:AUTL
- LAST PRICE4.1900
- TODAY'S CHANGE (%)-0.0900 (-2.1028%)
- Bid / Lots3.8000/ 2
- Ask / Lots4.3900/ 10
- Open / Previous Close4.2700 / 4.2800
- Day Range
- 52 Week Range
- Volume512,880
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AUTL |
|---|---|---|
| 09:32 ET | 9908 | 4.06 |
| 09:33 ET | 18000 | 3.86 |
| 09:35 ET | 8413 | 4 |
| 09:37 ET | 3600 | 3.95 |
| 09:39 ET | 2750 | 3.97 |
| 09:42 ET | 6654 | 3.97 |
| 09:44 ET | 500 | 3.9628 |
| 09:46 ET | 300 | 3.96 |
| 09:48 ET | 1980 | 3.9697 |
| 09:50 ET | 3806 | 4 |
| 09:51 ET | 3071 | 4.0359 |
| 09:53 ET | 5120 | 4.06 |
| 09:55 ET | 725 | 4.06 |
| 09:57 ET | 525 | 4.03 |
| 10:02 ET | 1996 | 4.04 |
| 10:04 ET | 5601 | 4.02 |
| 10:06 ET | 400 | 4.02 |
| 10:08 ET | 914 | 4.02 |
| 10:09 ET | 200 | 4.03 |
| 10:11 ET | 984 | 4.01 |
| 10:13 ET | 4722 | 4 |
| 10:15 ET | 1225 | 4 |
| 10:18 ET | 1123 | 3.98 |
| 10:20 ET | 500 | 3.975 |
| 10:22 ET | 400 | 3.975 |
| 10:24 ET | 1636 | 3.995 |
| 10:26 ET | 5290 | 4 |
| 10:27 ET | 6673 | 4.01 |
| 10:29 ET | 4784 | 4.015 |
| 10:33 ET | 200 | 4.015 |
| 10:36 ET | 4089 | 4.0101 |
| 10:38 ET | 5863 | 4.01 |
| 10:42 ET | 253 | 4.015 |
| 10:44 ET | 655 | 4.01 |
| 10:45 ET | 5571 | 4.015 |
| 10:47 ET | 1108 | 4.015 |
| 10:49 ET | 2019 | 4.055 |
| 10:51 ET | 1832 | 4.06 |
| 10:56 ET | 100 | 4.055 |
| 10:58 ET | 2999 | 4.05 |
| 11:02 ET | 449 | 4.05 |
| 11:03 ET | 300 | 4.05 |
| 11:05 ET | 2873 | 4.04 |
| 11:07 ET | 4065 | 4.065 |
| 11:09 ET | 1075 | 4.059 |
| 11:12 ET | 1407 | 4.07 |
| 11:14 ET | 2880 | 4.062 |
| 11:16 ET | 4040 | 4.1194 |
| 11:18 ET | 200 | 4.13 |
| 11:20 ET | 430 | 4.13 |
| 11:21 ET | 332 | 4.125 |
| 11:23 ET | 17867 | 4.15 |
| 11:25 ET | 100 | 4.15 |
| 11:27 ET | 2690 | 4.12 |
| 11:30 ET | 1656 | 4.13 |
| 11:32 ET | 1199 | 4.12 |
| 11:34 ET | 1112 | 4.12 |
| 11:36 ET | 2857 | 4.101 |
| 11:38 ET | 100 | 4.1 |
| 11:39 ET | 100 | 4.1 |
| 11:41 ET | 574 | 4.1 |
| 11:45 ET | 100 | 4.1 |
| 11:50 ET | 600 | 4.11 |
| 11:52 ET | 958 | 4.095 |
| 11:54 ET | 400 | 4.11 |
| 11:56 ET | 1149 | 4.11 |
| 11:57 ET | 3611 | 4.12 |
| 11:59 ET | 2871 | 4.13 |
| 12:01 ET | 5200 | 4.13 |
| 12:03 ET | 2306 | 4.12 |
| 12:06 ET | 1015 | 4.13 |
| 12:08 ET | 200 | 4.13 |
| 12:10 ET | 2870 | 4.13 |
| 12:12 ET | 26312 | 4.14 |
| 12:14 ET | 1300 | 4.13 |
| 12:15 ET | 400 | 4.12 |
| 12:17 ET | 854 | 4.11 |
| 12:19 ET | 300 | 4.11 |
| 12:21 ET | 300 | 4.11 |
| 12:24 ET | 2660 | 4.111 |
| 12:26 ET | 2777 | 4.1 |
| 12:28 ET | 2452 | 4.1 |
| 12:30 ET | 1800 | 4.1 |
| 12:32 ET | 3950 | 4.11 |
| 12:33 ET | 400 | 4.1 |
| 12:35 ET | 643 | 4.1 |
| 12:37 ET | 801 | 4.1 |
| 12:39 ET | 200 | 4.1 |
| 12:42 ET | 400 | 4.1 |
| 12:44 ET | 500 | 4.1 |
| 12:46 ET | 900 | 4.115 |
| 12:48 ET | 200 | 4.11 |
| 12:50 ET | 700 | 4.12 |
| 12:51 ET | 1953 | 4.1 |
| 12:53 ET | 100 | 4.0906 |
| 12:55 ET | 951 | 4.09 |
| 12:57 ET | 100 | 4.085 |
| 01:00 ET | 100 | 4.09 |
| 01:02 ET | 3541 | 4.08 |
| 01:04 ET | 1000 | 4.09 |
| 01:06 ET | 17480 | 4.12 |
| 01:08 ET | 3001 | 4.115 |
| 01:09 ET | 300 | 4.1 |
| 01:11 ET | 300 | 4.11 |
| 01:13 ET | 200 | 4.11 |
| 01:15 ET | 400 | 4.11 |
| 01:18 ET | 1393 | 4.09 |
| 01:20 ET | 200 | 4.11 |
| 01:22 ET | 1507 | 4.095 |
| 01:26 ET | 900 | 4.09 |
| 01:27 ET | 1807 | 4.12 |
| 01:29 ET | 1400 | 4.11 |
| 01:31 ET | 500 | 4.1175 |
| 01:33 ET | 525 | 4.11 |
| 01:36 ET | 1000 | 4.095 |
| 01:38 ET | 709 | 4.11 |
| 01:40 ET | 222 | 4.1085 |
| 01:42 ET | 100 | 4.11 |
| 01:44 ET | 400 | 4.11 |
| 01:45 ET | 100 | 4.11 |
| 01:47 ET | 500 | 4.1075 |
| 01:49 ET | 300 | 4.105 |
| 01:51 ET | 200 | 4.11 |
| 01:54 ET | 1398 | 4.13 |
| 01:56 ET | 200 | 4.14 |
| 01:58 ET | 3551 | 4.16 |
| 02:00 ET | 100 | 4.16 |
| 02:02 ET | 200 | 4.155 |
| 02:03 ET | 300 | 4.17 |
| 02:05 ET | 2745 | 4.15 |
| 02:09 ET | 300 | 4.135 |
| 02:14 ET | 1485 | 4.14 |
| 02:18 ET | 479 | 4.15 |
| 02:21 ET | 2722 | 4.14 |
| 02:23 ET | 550 | 4.14 |
| 02:25 ET | 1000 | 4.1491 |
| 02:27 ET | 963 | 4.145 |
| 02:30 ET | 700 | 4.15 |
| 02:32 ET | 2384 | 4.1412 |
| 02:34 ET | 600 | 4.15 |
| 02:36 ET | 1044 | 4.145 |
| 02:38 ET | 389 | 4.145 |
| 02:41 ET | 200 | 4.155 |
| 02:43 ET | 2013 | 4.155 |
| 02:45 ET | 1600 | 4.15 |
| 02:48 ET | 200 | 4.165 |
| 02:50 ET | 100 | 4.175 |
| 02:52 ET | 2924 | 4.1507 |
| 02:54 ET | 400 | 4.155 |
| 02:56 ET | 700 | 4.155 |
| 02:57 ET | 298 | 4.155 |
| 02:59 ET | 1292 | 4.155 |
| 03:01 ET | 200 | 4.155 |
| 03:03 ET | 745 | 4.155 |
| 03:06 ET | 300 | 4.155 |
| 03:08 ET | 5097 | 4.155 |
| 03:10 ET | 1039 | 4.155 |
| 03:12 ET | 395 | 4.155 |
| 03:14 ET | 1638 | 4.155 |
| 03:15 ET | 714 | 4.16 |
| 03:17 ET | 2363 | 4.145 |
| 03:19 ET | 1900 | 4.15 |
| 03:21 ET | 390 | 4.145 |
| 03:24 ET | 2611 | 4.135 |
| 03:26 ET | 625 | 4.135 |
| 03:28 ET | 300 | 4.135 |
| 03:30 ET | 1315 | 4.145 |
| 03:32 ET | 1682 | 4.155 |
| 03:33 ET | 400 | 4.155 |
| 03:35 ET | 902 | 4.155 |
| 03:37 ET | 1521 | 4.155 |
| 03:39 ET | 491 | 4.155 |
| 03:42 ET | 400 | 4.15 |
| 03:44 ET | 7146 | 4.15 |
| 03:46 ET | 4287 | 4.145 |
| 03:48 ET | 8271 | 4.165 |
| 03:50 ET | 9803 | 4.175 |
| 03:51 ET | 7737 | 4.172 |
| 03:53 ET | 8219 | 4.175 |
| 03:55 ET | 12290 | 4.175 |
| 03:57 ET | 9663 | 4.175 |
| 04:00 ET | 34790 | 4.19 |
Nov 29, 2023
DJ Autolus Therapeutics Price Target Maintained With a $7.00/Share by Needham, from 6:00AM ET on Wednesday Nov 29, 2023 by Dow Jones
6:00AM ET on Wednesday Nov 29, 2023 by Dow Jones
Nov 28, 2023
DJ Cabaletta Bio Down as FDA Looks Into Issues With Several Companies' Approved CAR T Drugs, from 2:29PM ET on Tuesday Nov 28, 2023 by Dow Jones
2:29PM ET on Tuesday Nov 28, 2023 by Dow JonesThinking about buying stock in Ardelyx, Autolus Therapeutics, SMX (Security Matters) PLC, Hudson Pacific Properties, or Dharma Polimetal?, from 9:31AM ET on Tuesday Nov 28, 2023 by Dow Jones
9:31AM ET on Tuesday Nov 28, 2023 by Dow Jones
Nov 27, 2023
DJ Autolus Seeks FDA OK of Obe-Cel in Adult B-Cell Acute Lymphoblastic Leukemia, from 7:24AM ET on Monday Nov 27, 2023 by Dow Jones
7:24AM ET on Monday Nov 27, 2023 by Dow JonesAutolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL), from 7:00AM ET on Monday Nov 27, 2023 by Dow Jones
7:00AM ET on Monday Nov 27, 2023 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Autolus Therapeutics PLC | 729.0M | -4.2x | --- |
Kura Oncology Inc | 739.8M | -4.9x | --- |
Ambrx Biopharma Inc | 781.8M | 0.0x | --- |
Hillevax Inc | 698.0M | -5.1x | --- |
Replimune Group Inc | 691.6M | -3.8x | --- |
Dyne Therapeutics Inc | 687.4M | -3.1x | --- |
Company Information
Autolus Therapeutics plc is a United Kingdom-based chimeric antigen receptor (CAR) T cell therapy company. The Company is developing programmed T cell therapies for the treatment of cancer. Using its suite of modular T cell programming technologies, the Company is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize cancer cells, break down their defense mechanisms and attack and kill these cells. Its clinical-stage pipeline comprises five programs developed in seven hematological and solid tumor indications. Its clinical-stage programs are Obe-cel (AUTO1), AUTO1/22, AUTO3, AUTO4, and AUTO6. AUTO1 is a CD19 CAR T cell investigational therapy designed to overcome the limitations in clinical activity and safety compared to current CD19 CAR T cell therapies. AUTO1/22 is a dual targeting CAR T cell-based therapy candidate based on obe-cel. AUTO3 is for the treatment of B-cell leukemias and lymphomas.
Contact Information
- Headquarters
- The Mediaworks, 191 Wood LaneLONDON, United Kingdom W12 7FP
- Phone
- 203-829-6230
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- John Johnson
- Chief Executive Officer, Executive Director
- Christian Itin
- Founder, Senior Vice President, Chief Scientific Officer
- Martin Pule
- Chief Financial Officer, Senior Vice President
- Lucinda Crabtree
- Chief Operating Officer, Senior Vice President
- Christopher Vann
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $729.0M |
|---|---|
Revenue (TTM) | $5.5M |
Shares Outstanding | 174.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.70 |
EPS | $-1.01 |
Book Value | --- |
P/E Ratio | -4.2x |
Price/Sales (TTM) | 132.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -3,170.43% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
